These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20052721)

  • 1. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.
    Moulder SL; Holmes FA; Tolcher AW; Thall P; Broglio K; Valero V; Buzdar AU; Arbuck SG; Seidman A; Hortobagyi GN
    Cancer; 2010 Feb; 116(4):814-21. PubMed ID: 20052721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
    Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
    J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
    Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
    Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
    Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
    J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.
    Smith RE; Brown AM; Mamounas EP; Anderson SJ; Lembersky BC; Atkins JH; Shibata HR; Baez L; DeFusco PA; Davila E; Tipping SJ; Bearden JD; Thirlwell MP
    J Clin Oncol; 1999 Nov; 17(11):3403-11. PubMed ID: 10550134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
    Nabholtz JM; Gelmon K; Bontenbal M; Spielmann M; Catimel G; Conte P; Klaassen U; Namer M; Bonneterre J; Fumoleau P; Winograd B
    J Clin Oncol; 1996 Jun; 14(6):1858-67. PubMed ID: 8656254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
    Ibrahim NK; Rahman Z; Valero V; Willey J; Theriault RL; Buzdar AU; Murray JL; Bast R; Hortobagyi GN
    Cancer; 1999 Oct; 86(7):1251-7. PubMed ID: 10506711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
    Martín M; Lluch A; Casado A; Garciía Carbonero I; de Paz L; Esteban C; Insa A; Alfonso R; García-Conde J; Diaz-Rubio E
    Ann Oncol; 2000 Jan; 11(1):85-9. PubMed ID: 10690393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
    Paridaens R; Biganzoli L; Bruning P; Klijn JG; Gamucci T; Houston S; Coleman R; Schachter J; Van Vreckem A; Sylvester R; Awada A; Wildiers J; Piccart M
    J Clin Oncol; 2000 Feb; 18(4):724-33. PubMed ID: 10673513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
    Seo JH; Whang YM; Kim BS; Choi CW; Shin SW; Kim YH; Kim JS; Goo BH
    Cancer; 2002 Apr; 94(7):1925-30. PubMed ID: 11932893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; Murillo SM; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G;
    Ann Oncol; 2018 Mar; 29(3):661-668. PubMed ID: 29228091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U; Harstrick A; Wilke H; Seeber S
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
    Rivera E; Holmes FA; Frye D; Valero V; Theriault RL; Booser D; Walters R; Buzdar AU; Dhingra K; Fraschini G; Hortobagyi GN
    Cancer; 2000 Dec; 89(11):2195-201. PubMed ID: 11147589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
    Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
    J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.